Bionovate applies to list on NASDAQ

Rhea-AI Summary

Bionovate Technologies Corp. (OTCPK:BIIO) has submitted a formal application for listing its shares on the NASDAQ Stock Exchange, the second-largest exchange by market capitalization. This move is part of the company's strategy to enter the rapidly growing medical device market. The application includes a Form 20-F Registration Statement filed with the SEC, and the company's acceptance depends on meeting NASDAQ's minimum listing requirements. Bionovate aims to innovate healthcare diagnostics through mobile applications and devices.

Positive

• Application submitted for NASDAQ listing, enhancing visibility.
• Strategic move into the fast-growing medical device market.
• Focus on digital transformation in healthcare diagnostics.

Negative

• Acceptance is contingent on meeting minimum NASDAQ requirements.
• Forward-looking statements indicate risks related to execution and market conditions.

CHAM, Switzerland, May 03, 2021 (GLOBE NEWSWIRE) -- Bionovate Technologies Corp., traded on OTC Markets (OTCPK:BIIO), announced that it has submitted a formal application to list its common shares (“Shares”) on the NASDAQ Stock Exchange (“NASDAQ”). NASDAQ is the second largest exchange by market capitalization worldwide and is home to many of the world’s best technology companies.

In connection with its application to list on NASDAQ, Bionovate will file a Form 20-F Registration Statement with the United States Securities and Exchange Commission (SEC). Acceptance for listing the Company’s shares is subject to approval based on several factors including satisfaction of minimum listing requirements for the NASDAQ Capital Market. The Company intends to satisfy all the applicable listing requirements. With the listing Bionovate is entering an important phase into a fast growing medical device market worldwide.

About Bionovate Technologies Corp.
Bionovate Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an ecosystem of medical devices and mobile applications to turn health care data into personal digital services with a great user experience on mobile devices. Innovations in this field are transforming some of the most promising, high-growth-opportunity segments in the medical device market worldwide.

Safe Harbor Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the use of the words "may," "will," "should," "plans," "expects," "anticipates," "continue," "estimates," "projects," "intends," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company's ability to successfully execute its expanded business strategy, including by entering into definitive agreements with suppliers, commercial partners and customers; general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in completing various engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technical advances and delivering technological innovations, shortages in components, production delays due to performance quality issues with outsourced components, regulatory requirements and the ability to meet them, government agency rules and changes, and various other factors beyond the Company's control.

Bionovate Technologies Corp.
Gewerbestr. 10
6330 Cham
Switzerland

Press contact:
Sandra Meyer
Tel: +41 581 01 02 02
Mail: press@bionovate.com

FAQ

What is Bionovate Technologies Corp.'s latest news regarding NASDAQ?

Bionovate Technologies Corp. has submitted an application to list its shares on NASDAQ.

What is the significance of Bionovate's NASDAQ application?

The NASDAQ listing is expected to enhance the company's visibility and access to capital in the medical device market.

What risks does Bionovate face with its NASDAQ listing?

The company must meet NASDAQ's minimum listing requirements and faces risks related to market conditions and execution of its business strategy.

What are Bionovate's business focuses?

Bionovate focuses on healthcare and lifestyle diagnostics through digital innovations and mobile applications.

What is the stock symbol for Bionovate Technologies Corp.?

The stock symbol for Bionovate Technologies Corp. is BIIO.